In resectable pancreatic cancer, neoantigen peptide-pulsed DC infusion led to detectable neoantigen-specific immunity in 81.3% of treated patients (29.4% of CD8+ and 25.0% of CD4+ T-cell responses), accompanied by a favorable clinical course in a substantial proportion of individuals. This evidence concerns the gene CD8A and familial pancreatic carcinoma.